Список литературы

1. Детская нефрология: практическое руководство под ред. Э. Лоймана, А.Н. Цыгина, А.А. Саркисяна. М.: Литтерра, 2010, 400 с.

2. Alper S.L. Familial renal tubular acidosis. J. Nephrol. 2010; 23 Suppl 16: 57 - 76.

3. Amin N., Alvi N.S., Barth J.H. et al. Pseudohypoaldosteronism type 1: clinical features and management in infancy. Endocrinol. Diabetes Metab. Case Rep. 2013; 2013: 130010

4. Batlle D., Haque S.K. Genetic causes and mechanisms of distal renal tubular acidosis. Nephrol. Dial. Transplant. 2012; 27 (10): 3691 - 3704

5. Carpenter T.O., Imel E.A., Holm I.A. et al. A clinician guide to X-linked hypophosphatemia. J. Bone Miner. Res. 2011; 26 (7): 1381 - 1388

6. Carpenter T.O., Olear E.A., Zhang J.H. et al. Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2014; 99 (9): 3103 - 3111

7. Elmonem M.A., Veys K.R., Soliman N.A. et al. Cystinosis: a review. Orphanet Journal of Rare Diseases. 2016; 11: 47

8. Emma F., Nesterova G., Langman C. et al. Nephropathic cystinosis: an international consensus document. Nephrol. Dial. Transplant. 2014; 29 Suppl. 4: 87 - 94

9. Fremont O.T., Chan J.C.M. Understanding Bartter syndrome and Gitelman syndrome. World Journal of Pediatrics. 2012; 8 (1): 25 - 30

10. Garovic V.D., Hilliard A.A., Turner S.T. Monogenic forms of low-renin hypertension. Nat. Clin. Pract. Nephrol. 2006; 2 (11): 624 - 630

11. Haque S.K., Ariceta G., Batlle D. Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrol. Dial. Transplant. 2012; 27 (12): 4273 - 4287

12. Katzir Z., Dinour D., Reznik-Wolf H. et al. Familial pure proximal renal tubular acidosis - a clinical and genetic study. Nephrol. Dial. Transplant. 2018; 23 (4): 1211 - 1215

13. Knoers NVAM, Levtchenko E.N. Gitelman syndrome. OJRD. 2008; 3 (1): 22

14. B.K, Bergler T., Stoelcker B., Waldegger S. Mechanisms of Disease: the kidney-specific chloride channels ClCKA and ClCKB, the Barttin subunit, and their clinical relevance. Nat. Clin. Pract. Nephrol. 2008; 4 (1): 38 - 46.

15. Langman C.B., Greenbaum L.A., Grimm P. et al. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate. J. Pediatr. 2014; 165 (3): 528 - 533.

16. Langman C.B., Greenbaum L.A., Sarwal M. et al. A randomized controlled crossover trial whith delayed-release cysteamine bitartrat in nephropathic cystinosis: Effectiveness on white blood cell cystine levels and comparison of safety. Clin. J. Am. Soc. Nephrol. 2012; 7 (7): 1112 - 1120

17. Lee J.Y., Imel E.A. The Changing Face of Hypophosphatemic Disorders in the FGF-23 Era. Pediatr. Endocrinol. Rev. 2013; 10 (02): 367 - 379.

18. Linglart A., Biosse-Duplan M., Briot K. et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr. Connect. 2014; 3 (1): 13 - 30

19. Mayan H., Vered I., Mouallem M. et al. Pseudohypoaldosteronism type II: marked sensitivity to thiazides, hypercalciuria, normomagnesemia, and low bone mineral density. J. Clin. Endocrinol. Metab. 2002; 87 (7): 3248 - 3254.

20. D. Familial renal glycosuria and modifications of glucose renal excretion. Diabetes Metab. 2014; 6 Suppl. 1: 12 - 16.

21. Puricelli E., Bettinelli A., Borsa N. et al. Long-term follow-up of patients with Bartter syndrome type I and II. Nephrol. Dial. Transplant. 2010; 25 (9): 2976 - 2981.

22. Riepe F.G. Clinical and Molecular Features of Type 1 Pseudohypoaldosteronism. Horm. Res. 2009; 72 (1): 1 - 9.

23. Santer R, Calado J. Familial renal glucosuria and SGLT2: from a mendelian trait to a therapeutic target. Clin. J. Am. Soc. Nephrol. 2010; 5 (1): 133 - 141.

24. Schrier R.W. Body water homeostasis: clinical disorders of urinary dilution and concentration. J. Am. Soc. Nephrol. 2006 (17): 1820 - 1832

25. Sirac C., Bridoux F, Essig M, Devuyst O, Touchard G, Cogne M. Toward understanding renal Fanconi syndrome: step by step advances through experimental models. Contrib. Nephrol. 2011; 169: 247 - 261.

26. Soylu A., Kasap B., Ogun N., Ozturk Y., Turkmen M., Hoefsloot L., Kavukcu S. Efficacy of COX-2 inhibitors in a case of congenital nephrogenic diabetes insipidus. Pediatr. Nephrol. 2005; 20: 1814 - 1817.

27. Wesche D., Deen PMT., Knoers NVAM. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr. Nephrol. 2012 (27): 2183 - 2204.

28. Zivicnjak M., Schnabel D., Staude H. et al. Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. J. Clin. Endocrinol. Metab. 2011; 96 (12): 2097 - 2105.